ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 19 Dec 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing sodium zirconium cyclosilicate on the MOH List of Subsidised Drugs for treating hyperkalaemia due to the uncertain extent of clinical benefit and uncertain cost effectiveness compared with current standard of care.


Sodium zirconium cyclosilicate for treating hyperkalaemia (19 December 2022) PES Sodium zirconium cyclosilicate for treating hyperkalaemia (19 December 2022)